Molecular Partners doses first patients in Phase 1/2a trial of DLL3 Radio-DARPin MP0712

(AWP Alliance News) - Molecular Partners said the first patients have been dosed in a US multicenter Phase 1/2a study of MP0712, a DLL3-targeting Radio-DARPin labeled with lead-212 for small cell lung cancer and other neuroendocrine tumors. The trial uses a matched-pair approach, starting with lead-203 imaging and dosimetry to predict tumor uptake before treatment.

Patients can receive up to four doses of lead-212 MP0712 across as many as four dose levels, with repeat dosing already underway in the first cohort. Initial data are expected in the coming months, with a more comprehensive safety and efficacy dataset targeted for 2027.

https://www.sec.gov/Archives/edgar/data/1745114/0001171843-26-004433-in…

Disclaimer: This news brief was created using generative artificial intelligence. Molecular Partners AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission, on July 02, 2026, and is solely responsible for the information contained therein.